NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

Assurant

(AIZ) - Get Report

was upgraded at Bank of America/Merrill Lynch to neutral. $60 price target. Company is seeing a pricing overhang easing in Florida, BofA/Merrill said.

Chesapeake Energy

(CHK) - Get Report

was downgraded at Stifel Nicolaus to hold from buy. Valuation call, given low expectations for production growth, Stifel Nicolaus said.

Emcor

(EME) - Get Report

was upgraded at DA Davidson to buy from neutral. Company is leveraged to a recovering nonresidential construction environment, DA Davidson said.

Corning

(GLW) - Get Report

downgraded at Piper Jaffray to neutral from overweight. $14 price target. Company lacks exposure to new product cycle in display.

Read: The Deal: Lloyds Offloads Remaining Australian Assets

JB Hunt

(JBHT) - Get Report

was upgraded at Bank of America/Merrill Lynch to buy from neutral. $81 price target. Company offers a strong secular growth story, BofA/Merrill said.

Johnson & Johnson

(JNJ) - Get Report

was upgraded at Goldman Sachs to neutral from sell. Pharma outlook is improving, Goldman said. $95 price target.

Life Technologies

(LIFE) - Get Report

was downgraded to hold at TheStreet Ratings.

Eli Lilly

(LLY) - Get Report

was downgraded at Jefferies to underperform from buy. Estimates were also lowered, given worsening business environment and disappointing R&D productivity, Jefferies said. $40 price target.

L Brands

(LTD)

was downgraded at Credit Suisse to neutral from outperform. $64 price target. Comp weakness persists and inventories are building, Credit Suisse said.

Merck

(MRK) - Get Report

was downgraded at Jefferies to hold from buy. Estimates were also decreased on weak business environment and unimpressive cost-cutting initiatives, Jefferies said. $50 price target.

Read: Wells Fargo Profits Rise, Defying JPMorgan Loss

Pharmacyclics

(PCYC)

was upgraded at Goldman Sachs to buy from neutral. $170 price target. ibruttinib could generate $7.5 billion of peak annual sales, Goldman said.

Premier Exhibitions

(PRXI)

was downgraded to sell at TheStreet Ratings.

Sonoco

(SON) - Get Report

was downgraded at Goldman Sachs to sell from neutral. Company will likely grow slower than its peers over the next few quarters, Goldman said.

Stock Comments / EPS Changes

Calpine

(CPN)

estimates, price target were reduced at UBS. Estimates were reduced through 2014. Company lowered its guidance, UBS said. Buy rating and new $22 price target.

Lowe's

(LOW) - Get Report

estimates, target upped at Credit Suisse. Estimates were boosted through 2015. Higher comp sales are driving gross margin expansion. Outperform rating and new $55 price target, Credit Suisse said.

Methanex

(MEOH) - Get Report

estimates, price target were raised at UBS. Shares are now seen reaching $59. Estimates were also increased, as the company is seeing higher reference pricing, UBS said. Buy rating.

Read: Here's Where Your Neighbors Like to Have Sex

Micron

(MU) - Get Report

estimates were increased at Jefferies. Elpida and DRAM ASPs contributing to income and gross margin, Jefferies said. Buy rating and $30 price target.

Micron estimates, price target were increased at UBS. DRAM pricing is moving higher, UBS said. Buy rating and new $23 price target.

>To submit a news tip, email:

tips@thestreet.com

.

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

This article was written by a staff member of TheStreet.